| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
The amount of CD8+ T cells infiltrating the cancer tissue can be a predictor of the survival time of the host and responsiveness to immunotherapy. It is considered that cancer stem cells also exist in solid tumors and are involved in treatment resistance. We have revealed several substances involved in cancer stem cells in gastric cancer. Among these substances, dCTPP1 has been suggested to be associated with the stemness of breast cancer. In this study, we investigated the clinical significance of tumor immunity and stemness in combination chemotherapy with pertuzumab in HER2-positive advanced breast cancer. Chemotherapy with combined targeting in HER2-positive advanced breast cancer revealed that stem cell-mediated involvement in systemic and local tumor immunity.
|
